Working… Menu
Trial record 5 of 228 for:    yeast

Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01687049
Recruitment Status : Unknown
Verified November 2012 by Dr. Laurence Klotz, Sunnybrook Health Sciences Centre.
Recruitment status was:  Not yet recruiting
First Posted : September 18, 2012
Last Update Posted : November 7, 2012
Information provided by (Responsible Party):
Dr. Laurence Klotz, Sunnybrook Health Sciences Centre

Brief Summary:
Agents that inhibit cholesterol synthesis are being investigated in cancers dependent upon cholesterogenesis. Red yeast rice (RYR), is a reddish-purple fermented rice, containing statins which are known to inhibit cholesterol synthesis. Laboratory studies have also shown that RYR has direct effects on androgen dependent and androgen independent prostate cancer cells, inhibiting their growth. It is thought that RYR may have clinical benefit in those subjects with localized prostate cancer who have chosen to be managed by active surveillance.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Red yeast rice Phase 2

Detailed Description:
Red yeast rice has been promoted as a safe and effective alternative to statin therapy in the treatment of hypercholesterolemia. Red yeast rice has the potential to slow prostate cancer growth by inhibiting cholesterol and androgen biosynthesis. There is a strong rationale for the use of RYR in patients being managed with active surveillance for localized, low risk, prostate cancer. To date, no human studies utilizing RYR in this setting have been reported.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Study of Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Study Start Date : January 2013
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: red yeast rice (RYR)
Two RYR capsules three times daily for a minimum of 6 months
Drug: Red yeast rice
Other Name: Aliperol

Primary Outcome Measures :
  1. Expression of Ki-67 and p27 biomarkers [ Time Frame: 6 months ]
    Determine effect of red yeast rice therapy on expression of ki67 and p27 biomarkers in a post-treatment biopsy

Secondary Outcome Measures :
  1. PSA kinetics [ Time Frame: 6 months ]
    Determine effect of red yeast rice daily therapy on PSA kinetics in men on active surveillance for localized prostate cancer

  2. Presence of prostatic interepithelial neoplasia [ Time Frame: 6 months ]
    To evaluate the effect of red yeast rice daily therapy on grade and the presence of prostatic intraepithelial neoplasia (PIN) in post treatment biopsy

  3. Expression of hs-CRP and cardiac CRP [ Time Frame: 6 months ]
    To assess the effect of red yeast rice therapy on the expression of high sensitivity C-reactive protein (hs-CRP) and cardiac C-reactive protein (CRP) in serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically diagnosis of prostate adenocarcinoma
  • being monitored by active surveillance for favourable risk prostate cancer
  • tumour material from most recent prostate biopsy available with sample
  • scheduled to have an active surveillance mandated transrectal ultrasound (TRUS) guided biopsy within 6 - 12 months of Day 1 of the study

Exclusion Criteria:

  • previous malignancy in the past 5 years
  • no previous or concurrent treatment for prostate cancer
  • inability to undergo TRUS biopsy
  • ECOG > 2
  • known or previous history of liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01687049

Layout table for location contacts
Contact: Marlene Kebabdjian, BA 416-480-6100 ext 7939

Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre Not yet recruiting
Toronto, Ontario, Canada, M4N 3M5
Principal Investigator: Laurence Klotz, Md         
Sponsors and Collaborators
Dr. Laurence Klotz
Layout table for investigator information
Principal Investigator: Laurence Klotz, MD Sunnybrook Health Sciences Centre

Layout table for additonal information
Responsible Party: Dr. Laurence Klotz, Principal Investigator, Sunnybrook Health Sciences Centre Identifier: NCT01687049     History of Changes
Other Study ID Numbers: REALITY
SHSC ( Other Identifier: Urology Research, Sunnybrook Health Sciences Centre )
First Posted: September 18, 2012    Key Record Dates
Last Update Posted: November 7, 2012
Last Verified: November 2012
Keywords provided by Dr. Laurence Klotz, Sunnybrook Health Sciences Centre:
active surveillance
Additional relevant MeSH terms:
Layout table for MeSH terms
Red yeast rice
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents